🎉 M&A multiples are live!
Check it out!

Sumitomo Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Sumitomo Pharma and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Sumitomo Pharma Overview

About Sumitomo Pharma

Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.


Founded

1897

HQ

Japan
Employees

6.1K+

Financials

LTM Revenue $2.5B

LTM EBITDA $374M

EV

$3.2B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Sumitomo Pharma Financials

Sumitomo Pharma has a last 12-month revenue of $2.5B and a last 12-month EBITDA of $374M.

In the most recent fiscal year, Sumitomo Pharma achieved revenue of $2.1B and an EBITDA of -$1.9B.

Sumitomo Pharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Sumitomo Pharma valuation multiples based on analyst estimates

Sumitomo Pharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $3.7B $2.1B XXX XXX XXX
Gross Profit $2.7B $2.5B XXX XXX XXX
Gross Margin 73% 120% XXX XXX XXX
EBITDA -$23.2M -$1.9B XXX XXX XXX
EBITDA Margin -1% -89% XXX XXX XXX
Net Profit $375M -$495M XXX XXX XXX
Net Margin 10% -24% XXX XXX XXX
Net Debt $439M $1.3B XXX XXX XXX

Financial data powered by Morningstar, Inc.

Sumitomo Pharma Stock Performance

As of April 15, 2025, Sumitomo Pharma's stock price is JPY 518 (or $3).

Sumitomo Pharma has current market cap of JPY 206B (or $1.4B), and EV of JPY 478B (or $3.2B).

See Sumitomo Pharma trading valuation data

Sumitomo Pharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$3.2B $1.4B XXX XXX XXX XXX $0.20

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Sumitomo Pharma Valuation Multiples

As of April 15, 2025, Sumitomo Pharma has market cap of $1.4B and EV of $3.2B.

Sumitomo Pharma's trades at 1.3x LTM EV/Revenue multiple, and 8.5x LTM EBITDA.

Analysts estimate Sumitomo Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Sumitomo Pharma and 10K+ public comps

Sumitomo Pharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $3.2B XXX XXX XXX
EV/Revenue 1.3x XXX XXX XXX
EV/EBITDA -16.6x XXX XXX XXX
P/E -2.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 19.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Sumitomo Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Sumitomo Pharma Valuation Multiples

Sumitomo Pharma's NTM/LTM revenue growth is 2%

Sumitomo Pharma's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.6M for the same period.

Over next 12 months, Sumitomo Pharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Sumitomo Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Sumitomo Pharma and other 10K+ public comps

Sumitomo Pharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -43% XXX XXX XXX XXX
EBITDA Margin -8% XXX XXX XXX XXX
EBITDA Growth 7935% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -6% XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $0.6M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 137% XXX XXX XXX XXX
R&D Expenses to Revenue 36% XXX XXX XXX XXX
Opex to Revenue 173% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Sumitomo Pharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Sumitomo Pharma M&A and Investment Activity

Sumitomo Pharma acquired  XXX companies to date.

Last acquisition by Sumitomo Pharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . Sumitomo Pharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Sumitomo Pharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Sumitomo Pharma

When was Sumitomo Pharma founded? Sumitomo Pharma was founded in 1897.
Where is Sumitomo Pharma headquartered? Sumitomo Pharma is headquartered in Japan.
How many employees does Sumitomo Pharma have? As of today, Sumitomo Pharma has 6.1K+ employees.
Is Sumitomo Pharma publicy listed? Yes, Sumitomo Pharma is a public company listed on TKS.
What is the stock symbol of Sumitomo Pharma? Sumitomo Pharma trades under 4506 ticker.
When did Sumitomo Pharma go public? Sumitomo Pharma went public in 1949.
Who are competitors of Sumitomo Pharma? Similar companies to Sumitomo Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Sumitomo Pharma? Sumitomo Pharma's current market cap is $1.4B
What is the current revenue of Sumitomo Pharma? Sumitomo Pharma's last 12-month revenue is $2.5B.
What is the current EBITDA of Sumitomo Pharma? Sumitomo Pharma's last 12-month EBITDA is $374M.
What is the current EV/Revenue multiple of Sumitomo Pharma? Current revenue multiple of Sumitomo Pharma is 1.3x.
What is the current EV/EBITDA multiple of Sumitomo Pharma? Current EBITDA multiple of Sumitomo Pharma is 8.5x.
What is the current revenue growth of Sumitomo Pharma? Sumitomo Pharma revenue growth between 2023 and 2024 was -43%.
Is Sumitomo Pharma profitable? Yes, Sumitomo Pharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.